NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036PUBT·Jul 15 at 08:03 AMNCEL-1.18%
NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory boardPUBT·Jul 8 at 08:15 AMNCEL-1.18%ELDN-4.28%
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | NCEL Stock NewsStockTitan·Jul 8 at 12:15 AMNCEL-1.18%ELDN-4.28%
NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial planPUBT·Jul 2 at 01:32 PMNCEL-1.18%ELDN-4.28%
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | NCEL Stock NewsStockTitan·Jul 1 at 12:30 AMNCEL-1.18%ELDN-4.28%
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple SclerosisTip Ranks·Jun 15 at 08:11 AMNCEL-1.18%
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submissionbenzinga_article·May 27 at 06:31 AMNCEL-1.18%
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | NCEL Stock NewsStockTitan·May 26 at 10:55 PMNCEL-1.18%
